MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Efficacy of IncobotulinumtoxinA for the Treatment Of Shoulder Spasticity

D. Simpson, J. Wissel, D. Bensmail, A. Scheschonka, B. Flatau-Baqué, O. Simon (New York, NY, USA)

Meeting: 2017 International Congress

Abstract Number: 1152

Keywords: Botulinum toxin: Clinical applications: spasticity, Spasticity: Treatment

Session Information

Date: Wednesday, June 7, 2017

Session Title: Spasticity

Session Time: 1:15pm-2:45pm

Location: Exhibit Hall C

Objective: To evaluate efficacy of botulinum toxin for shoulder spasticity using a post-hoc analysis.

Background: Botulinum toxin has been shown to be effective for treating upper-limb spasticity, but there are few studies on the efficacy of botulinum toxin for use in the shoulder. Using botulinum toxin to treat the shoulder is challenging because of proximity to respiratory muscles. However, successful treatment of this area may be important for patients with respect to quality of life (QoL). The TOWER study examined the efficacy and safety of escalating doses of incobotulinumtoxinA for upper- and lower-limb spasticity. Seven upper limb clinical patterns were treated and evaluated, including the shoulder.

Methods: 155 subjects were treated in 3 treatment cycles with escalating fixed doses of incobotulinumtoxinA (400U, 600U and 600–800U). Study assessments included muscle tone (Ashworth Scale; AS) for all clinical patterns, quality of life (QoL; EQ-5D instrument) and adverse events. Using a post-hoc analysis, subjects who received treatment in the shoulder were compared with those who did not. The individual AS scores for shoulder adductors, extensors, and internal rotators were combined to calculate an AS shoulder sumscore (AS-SSS).

Results: Eighty-four subjects received incobotulinumtoxinA treatment in the shoulder in cycle 3 (mean [standard deviation; SD] shoulder dose 118.4 [60.2]U), and 57 subjects did not. The mean [SD] AS-SSS improvement among treated subjects during cycle 3 was -1.7 [1.8], compared with -0.9 [1.4] for untreated subjects. A significant dose dependence for effect of incobotulinumtoxinA on AS-SSS (P=0.0081) was revealed using multiple regression analysis (adjusting for AS-SSS baseline). Improvements in shoulder muscle tone were similar to AS score improvements for other upper limb clinical patterns. All dimensions of the EQ-5D improved across injection cycles. There were no treatment-related AEs indicating toxin spread from the shoulder to the lung (eg, respiratory depression).

Conclusions: This post-hoc analysis demonstrates that incobotulinumtoxinA is safe and effective for the treatment of shoulder spasticity and supports further clinical evaluation.

To cite this abstract in AMA style:

D. Simpson, J. Wissel, D. Bensmail, A. Scheschonka, B. Flatau-Baqué, O. Simon. Efficacy of IncobotulinumtoxinA for the Treatment Of Shoulder Spasticity [abstract]. Mov Disord. 2017; 32 (suppl 2). https://www.mdsabstracts.org/abstract/efficacy-of-incobotulinumtoxina-for-the-treatment-of-shoulder-spasticity/. Accessed June 15, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/efficacy-of-incobotulinumtoxina-for-the-treatment-of-shoulder-spasticity/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley